Northern Trust’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.3M Buy
2,720,444
+76,231
+3% +$1.09M 0.01% 1255
2025
Q4
$37.7M Sell
2,644,213
-693,162
-21% -$6.81M ﹤0.01% 1286
2025
Q3
$26.3M Buy
3,337,375
+247,569
+8% +$1.76M ﹤0.01% 1515
2025
Q2
$17.7M Sell
3,089,806
-285,320
-8% -$1.84M ﹤0.01% 1714
2025
Q1
$27.5M Buy
3,375,126
+3,487
+0.1% +$32.3K ﹤0.01% 1438
2024
Q4
$31.8M Buy
3,371,639
+187,652
+6% +$1.95M ﹤0.01% 1416
2024
Q3
$34M Buy
3,183,987
+136,633
+4% +$1.49M 0.01% 1287
2024
Q2
$30.2M Sell
3,047,354
-108,728
-3% -$1.12M 0.01% 1297
2024
Q1
$37.2M Buy
3,156,082
+311,331
+11% +$3.98M 0.01% 1192
2023
Q4
$40.4M Buy
2,844,751
+12,821
+0.5% +$146K 0.01% 1156
2023
Q3
$34.4M Buy
2,831,930
+15,608
+0.6% +$201K 0.01% 1177
2023
Q2
$35.4M Buy
2,816,322
+99,488
+4% +$1.18M 0.01% 1199
2023
Q1
$30.1M Buy
2,716,834
+19,261
+0.7% +$237K 0.01% 1288
2022
Q4
$32.9M Buy
2,697,573
+33,885
+1% +$381K 0.01% 1195
2022
Q3
$27.8M Sell
2,663,688
-30,413
-1% -$339K 0.01% 1246
2022
Q2
$28.9M Buy
2,694,101
+5,461
+0.2% +$45K 0.01% 1280
2022
Q1
$25.5M Sell
2,688,640
-106,397
-4% -$998K ﹤0.01% 1505
2021
Q4
$32.3M Sell
2,795,037
-35,963
-1% -$401K 0.01% 1434
2021
Q3
$27M Sell
2,831,000
-124,285
-4% -$1.27M ﹤0.01% 1570
2021
Q2
$28.5M Sell
2,955,285
-5,431
-0.2% -$53K 0.01% 1635
2021
Q1
$29.3M Sell
2,960,716
-265,189
-8% -$4.1M 0.01% 1555
2020
Q4
$74.5M Sell
3,225,905
-78,592
-2% -$1.61M 0.01% 800
2020
Q3
$46.7M Sell
3,304,497
-205,250
-6% -$2.99M 0.01% 968
2020
Q2
$52.9M Buy
3,509,747
+142,231
+4% +$1.73M 0.01% 849
2020
Q1
$31.1M Buy
3,367,516
+38,667
+1% +$368K 0.01% 1094
2019
Q4
$32.4M Buy
3,328,849
+70,440
+2% +$645K 0.01% 1349
2019
Q3
$26.1M Buy
3,258,409
+598,798
+23% +$6.5M 0.01% 1467
2019
Q2
$33.2M Buy
2,659,611
+136,521
+5% +$1.73M 0.01% 1315
2019
Q1
$34.3M Buy
2,523,090
+80,700
+3% +$986K 0.01% 1274
2018
Q4
$23.4M Sell
2,442,390
-3,487
-0.1% -$38.3K 0.01% 1449
2018
Q3
$29.6M Buy
2,445,877
+51,387
+2% +$719K 0.01% 1467
2018
Q2
$37.4M Buy
2,394,490
+203,444
+9% +$3.08M 0.01% 1266
2018
Q1
$33M Buy
2,191,046
+219,558
+11% +$3.34M 0.01% 1319
2017
Q4
$28.4M Sell
1,971,488
-5,371
-0.3% -$73.8K 0.01% 1439
2017
Q3
$29.8M Buy
1,976,859
+238,849
+14% +$3.16M 0.01% 1391
2017
Q2
$17.5M Buy
1,738,010
+52,569
+3% +$423K ﹤0.01% 1771
2017
Q1
$12M Buy
1,685,441
+71,599
+4% +$453K ﹤0.01% 1987
2016
Q4
$8.02M Buy
1,613,842
+13,726
+0.9% +$95K ﹤0.01% 2249
2016
Q3
$11.8M Buy
1,600,116
+164,436
+11% +$1.11M ﹤0.01% 1954
2016
Q2
$7.84M Buy
1,435,680
+118,138
+9% +$826K ﹤0.01% 2181
2016
Q1
$11.1M Buy
1,317,542
+19,034
+1% +$135K ﹤0.01% 1896
2015
Q4
$12.6M Buy
1,298,508
+34,967
+3% +$315K ﹤0.01% 1832
2015
Q3
$17.7M Buy
1,263,541
+1,019,446
+418% +$16M 0.01% 1584
2015
Q2
$3.45M Buy
244,095
+78,941
+48% +$949K ﹤0.01% 2755
2015
Q1
$1.8M Buy
165,154
+18,149
+12% +$160K ﹤0.01% 3179
2014
Q4
$1.22M Buy
147,005
+58,347
+66% +$400K ﹤0.01% 3327
2014
Q3
$528K Sell
88,658
-236,266
-73% -$1.24M ﹤0.01% 3552
2014
Q2
$1.09M Sell
324,924
-76,526
-19% -$180K ﹤0.01% 3365
2014
Q1
$831K Sell
401,450
-25,142
-6% -$62.9K ﹤0.01% 3435
2013
Q4
$1M Buy
426,592
+4,358
+1% +$9.57K ﹤0.01% 3378
2013
Q3
$979K Sell
422,234
-4,264
-1% -$10.7K ﹤0.01% 3335
2013
Q2
$993K Buy
+426,498
New +$1.31M ﹤0.01% 3275

Other funds holding FOLD

Northern Trust's FOLD Position: Q1 2026 in Review

Northern Trust increased its Amicus Therapeutics (FOLD) stake by 2.9% in Q1 2026, buying an estimated $1.09M and bringing the position to 2,720,444 shares worth $39.3M. The position accounts for 0.01% of the portfolio, ranked #1255.

Northern Trust first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $74.5M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Northern Trust held 2,720,444 shares of Amicus Therapeutics worth $39.3M as of Q1 2026.
  • Northern Trust bought 76,231 Amicus Therapeutics shares in Q1 2026, an estimated $1.09M.
  • Amicus Therapeutics made up 0.01% of Northern Trust's portfolio in Q1 2026, its #1255 holding.
  • Northern Trust first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Amicus Therapeutics position peaked at $74.5M in Q4 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.